Sonodynamic therapy (SDT), a procedure related with photodynamic therapy, is a promising new modality for treating deep-seated cancer.

1. Published on Meeting Library (http://meetinglibrary.asco.org)
Home > 130361-144
Primary clinical use of the sono-photo-dynamic therapy for advanced
esophagocadiac and gastric adenocarcinoma.
Meeting:
2014 ASCO Annual Meeting
Category:
Gastrointestinal (Noncolorectal) Cancer
Subcategory:
Esophageal or Gastric Cancer
Session Type and Session Title:
This abstract will not be presented at the 2014 ASCO Annual Meeting but
has been published in conjunction with the meeting.
Abstract Number:
e15024
Citation:
J Clin Oncol 32, 2014 (suppl; abstr e15024)
Author(s):
Lucy Qing Li, Xiaohuai Wang, Iris Wenyin Zhang, Douglas Mitchell; EEC
Bio-tech Co Ltd, Guangzhou, China; Liu Hua Qiao Hospital, Guangzhou,
China; Southern Medical University Renkang Hospital, Dongguan, China;
Science Group Pty Ltd, Melbourne, Australia
Background: Sonodynamic therapy (SDT), a procedure related with
photodynamic therapy, is a promising new modality for treating deep-seated
cancer. Two new chlorophyll derived sono-photo-sensitizing agents, along
with ultrasound equipment for systemic treatment (SDT), have been
developed by EEC Biotech and all approved by regulator for safety on
human. Animal studies demonstrate that the sensitizers are specifically
absorbed into tumor cells and SDT does inhibit growth of mouse S-180
sarcoma. An in vitro experiment with human breast and lung cancer
cell-lines showed that SDT was strongly synergetic with chemotherapy. We
reported before about using sono-photo-dynamic therapy (SPDT, a
combination therapy of SDT and PDT ) as a supplementary or salvage
treatment in advanced breast cancer, and now report some positive results in
advanced esophageal and gastric cancer by using SPDT. Methods: Seven
patients were pathologically proven advanced esophagocadiac and gastric
adenocarcinoma. 3 patients had conventional chemotherapy before. With
SPDT, Patients took the sensitizers sublingually on day 1 and 2; red light
and multiple ultrasound transducers irradiate tumor area and whole body on
day 4 to 6. The treatment was repeated. All patients had concurrent chemo

2. with range from moderate to 1/2 conventional dosages selected to keep side
effects at grade II or better. 2 patients received local radiation therapy as
well. Results: The seven patients achieved CR 3(42.8%), PR 3 (42.8%),
MR 1, with an overall response rate of 85%. The main SPDT side effects
were easily reversible mild pain in tumor areas, tiredness and weakness.
There was no skin sensitivity. SPDT/dose controlled chemo was well
tolerated, even along with the radiation therapy. Conclusions: These
preliminary data suggest that SPDT has almost no toxicity, but may
dramatically enhance the conventional therapeutic efficacy in advanced
refractory esophagocadiac and gastric adenocarcinoma. SPDT has a good
trend to be a new systemic, low toxicity tumor therapy and merit for further
investigation.
Source URL: http://meetinglibrary.asco.org/content/130361-144